Key result
IABP-SHOCK II risk score stratifies cardiogenic shock patients, predicting ~77% 30-day mortality in high-risk cases.
Why the study?
Mortality in cardiogenic shock remains high, making early risk stratification crucial for adequate treatment decisions, but an easy-to-use risk prediction score for short-term mortality was needed.
Can the IABP-SHOCK II risk score accurately predict 30-day mortality in patients with cardiogenic shock after acute myocardial infarction?
Observational
Can the IABP-SHOCK II risk score accurately predict 30-day mortality in patients with cardiogenic shock after acute myocardial infarction?
The IABP-SHOCK II risk score is a simple, 6-variable tool that effectively stratifies 30-day mortality risk in patients with infarct-related cardiogenic shock.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The IABP-SHOCK II risk score is a simple tool that can be rapidly calculated in the catheterization laboratory setting and applied in clinical routine. It might therefore serve for identifying patients for future clinical trials and, more importantly, it might help stratify patients according to their risk for short-term mortality and thus facilitate clinical decision-making.”
“This is a huge clinical question now: how do we make an impact on the persistently high mortality despite early revascularization? Obviously [the introduction of] early revascularization was a huge improvement in care with a marked reduction in mortality, but we've been stuck ever since, with no further advance.”
“While enhancing simplicity, dichotomization of continuous variables in a risk score can lead to overestimation or underestimation of risk, particularly for patients with values hovering around the selected cut points.”
May support early risk stratification in cardiogenic shock; leaves open external validation before clinical adoption.
BACKGROUND: Mortality in cardiogenic shock (CS) remains high. Early risk stratification is crucial to make adequate treatment decisions. OBJECTIVES: This study sought to develop an easy-to-use, readily available risk prediction score for short-term mortality in patients with CS, derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial. METHODS: The score was developed using a stepwise multivariable regression analysis. RESULTS: Six variables emerged as independent predictors for 30-day mortality and were used as score parameters: age >73 years, prior stroke, glucose at admission >10.6 mmol/l (191 mg/dl), creatinine at admission >132.6 μmol/l (1.5 mg/dl), Thrombolysis In Myocardial Infarction flow grade <3 after percutaneous coronary intervention, and arterial blood lactate at admission >5 mmol/l. Either 1 or 2 points were attributed to each variable, leading to a score in 3 risk categories: low (0 to 2), intermediate (3 or 4), and high (5 to 9). The observed 30-day mortality rates were 23.8%, 49.2%, and 76.6%, respectively (p < 0.0001). Validation in the IABP-SHOCK II registry population showed good discrimination with an area under the curve of 0.79. External validation in the CardShock trial population (n = 137) showed short-term mortality rates of 28.0% (score 0 to 2), 42.9% (score 3 to 4), and 77.3% (score 5 to 9; p < 0.001) and an area under the curve of 0.73. Kaplan-Meier analysis revealed a stepwise increase in mortality between the different score categories (0 to 2 vs. 3 to 4: p = 0.04; 0 to 2 vs. 5 to 9: p = 0.008). CONCLUSIONS: The IABP-SHOCK II risk score can be easily calculated in daily clinical practice and strongly correlated with mortality in patients with infarct-related CS. It may help stratify patient risk for short-term mortality and might, thus, facilitate clinical decision making. (Intraaortic Balloon Pump in Cardiogenic Shock II [IABP-SHOCK II]; NCT00491036).
No takes yet. Share an insight, caveat, or question.
Pöss et al. (2017) conducted an observational in Cardiogenic shock after acute myocardial infarction. IABP-SHOCK II risk score vs. Low risk score category was evaluated on 30-day mortality (p=< 0.0001). The IABP-SHOCK II risk score stratified 30-day mortality in cardiogenic shock patients into low, intermediate, and high risk categories.
Synapse has enriched 10 related papers. Consider them for comparative context: